Literature DB >> 22238455

IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells.

Osamu Imataki1, Sascha Ansén, Makito Tanaka, Marcus O Butler, Alla Berezovskaya, Matthew I Milstein, Kiyotaka Kuzushima, Lee M Nadler, Naoto Hirano.   

Abstract

Although both MHC class II/CD8α double-knockout and CD8β null mice show a defect in the development of MHC class I-restricted CD8(+) T cells in the thymus, they possess low numbers of high-avidity peripheral CTL with limited clonality and are able to contain acute and chronic infections. These in vivo data suggest that the CD8 coreceptor is not absolutely necessary for the generation of Ag-specific CTL. Lack of CD8 association causes partial TCR signaling because of the absence of CD8/Lck recruitment to the proximity of the MHC/TCR complex, resulting in suboptimal MAPK activation. Therefore, there should exist a signaling mechanism that can supplement partial TCR activation caused by the lack of CD8 association. In this human study, we have shown that CD8-independent stimulation of Ag-specific CTL previously primed in the presence of CD8 coligation, either in vivo or in vitro, induced severely impaired in vitro proliferation. When naive CD8(+) T cells were primed in the absence of CD8 binding and subsequently restimulated in the presence of CD8 coligation, the proliferation of Ag-specific CTL was also severely hampered. However, when CD8-independent T cell priming and restimulation were supplemented with IL-21, Ag-specific CD8(+) CTL expanded in two of six individuals tested. We found that IL-21 rescued partial MAPK activation in a STAT3- but not STAT1-dependent manner. These results suggest that CD8 coligation is critical for the expansion of postthymic peripheral Ag-specific CTL in humans. However, STAT3-mediated IL-21 signaling can supplement partial TCR signaling caused by the lack of CD8 association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238455      PMCID: PMC3273545          DOI: 10.4049/jimmunol.1003446

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

Review 2.  Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation.

Authors:  Grégory Verdeil; Julie Chaix; Anne-Marie Schmitt-Verhulst; Nathalie Auphan-Anezin
Journal:  Eur J Immunol       Date:  2006-12       Impact factor: 5.532

3.  Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells.

Authors:  B Hemmer; I Stefanova; M Vergelli; R N Germain; R Martin
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

4.  Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.

Authors:  B Kessler; D Hudrisier; M Schroeter; J Tschopp; J C Cerottini; I F Luescher
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

5.  Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis.

Authors:  J Li; W Shen; K Kong; Z Liu
Journal:  Scand J Immunol       Date:  2006-11       Impact factor: 3.487

6.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

Authors:  C Yee; P A Savage; P P Lee; M M Davis; P D Greenberg
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

7.  Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.

Authors:  Marcus O Butler; Jeng-Shin Lee; Sascha Ansén; Donna Neuberg; F Stephen Hodi; Andrew P Murray; Linda Drury; Alla Berezovskaya; Richard C Mulligan; Lee M Nadler; Naoto Hirano
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

8.  Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface.

Authors:  Linda Wooldridge; Hugo A van den Berg; Meir Glick; Emma Gostick; Bruno Laugel; Sarah L Hutchinson; Anita Milicic; Jason M Brenchley; Daniel C Douek; David A Price; Andrew K Sewell
Journal:  J Biol Chem       Date:  2005-04-18       Impact factor: 5.157

9.  Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties.

Authors:  Bruno Laugel; Hugo A van den Berg; Emma Gostick; David K Cole; Linda Wooldridge; Jonathan Boulter; Anita Milicic; David A Price; Andrew K Sewell
Journal:  J Biol Chem       Date:  2007-05-31       Impact factor: 5.157

10.  CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions.

Authors:  Bruno Laugel; David A Price; Anita Milicic; Andrew K Sewell
Journal:  Eur J Immunol       Date:  2007-04       Impact factor: 5.532

View more
  8 in total

1.  Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.

Authors:  Toshiki Ochi; Munehide Nakatsugawa; Kenji Chamoto; Shinya Tanaka; Yuki Yamashita; Tingxi Guo; Hiroshi Fujiwara; Masaki Yasukawa; Marcus O Butler; Naoto Hirano
Journal:  Cancer Immunol Res       Date:  2015-05-05       Impact factor: 11.151

2.  Tumor-infiltrating lymphocytes (TILs) from patients with glioma.

Authors:  Zhenjiang Liu; Qingda Meng; Jiri Bartek; Thomas Poiret; Oscar Persson; Lalit Rane; Elena Rangelova; Christopher Illies; Inti Harvey Peredo; Xiaohua Luo; Martin Vijayakumar Rao; Rebecca Axelsson Robertson; Ernest Dodoo; Markus Maeurer
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

3.  Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.

Authors:  Kenji Sugata; Yukiko Matsunaga; Yuki Yamashita; Munehide Nakatsugawa; Tingxi Guo; Levon Halabelian; Yota Ohashi; Kayoko Saso; Muhammed A Rahman; Mark Anczurowski; Chung-Hsi Wang; Kenji Murata; Hiroshi Saijo; Yuki Kagoya; Dalam Ly; Brian D Burt; Marcus O Butler; Tak W Mak; Naoto Hirano
Journal:  Nat Biotechnol       Date:  2021-03-01       Impact factor: 54.908

4.  Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.

Authors:  Kenji Chamoto; Tingxi Guo; Stephen W Scally; Yuki Kagoya; Mark Anczurowski; Chung-Hsi Wang; Muhammed A Rahman; Kayoko Saso; Marcus O Butler; Priscilla P L Chiu; Jean-Philippe Julien; Naoto Hirano
Journal:  J Immunol       Date:  2016-12-21       Impact factor: 5.422

5.  Specific roles of each TCR hemichain in generating functional chain-centric TCR.

Authors:  Munehide Nakatsugawa; Yuki Yamashita; Toshiki Ochi; Shinya Tanaka; Kenji Chamoto; Tingxi Guo; Marcus O Butler; Naoto Hirano
Journal:  J Immunol       Date:  2015-02-20       Impact factor: 5.422

6.  Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.

Authors:  Mohammad Haque; Jianyong Song; Kristin Fino; Praneet Sandhu; Youfei Wang; Bing Ni; Deyu Fang; Jianxun Song
Journal:  Cell Transplant       Date:  2016-01-15       Impact factor: 4.064

7.  Induction of autoimmune diabetes in non-obese diabetic mice requires interleukin-21-dependent activation of autoreactive CD8⁺ T cells.

Authors:  X-L Chen; D Bobbala; G M Rodriguez; M Mayhue; Y-G Chen; S Ilangumaran; S Ramanathan
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

8.  CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells.

Authors:  Munehide Nakatsugawa; Muhammed A Rahman; Yuki Yamashita; Toshiki Ochi; Piotr Wnuk; Shinya Tanaka; Kenji Chamoto; Yuki Kagoya; Kayoko Saso; Tingxi Guo; Mark Anczurowski; Marcus O Butler; Naoto Hirano
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.